search
Back to results

Kidney Protection Using the RenalGuard® System in Cardiac Surgery (KIDNEY)

Primary Purpose

Acute Renal Injury

Status
Completed
Phase
Not Applicable
Locations
United Kingdom
Study Type
Interventional
Intervention
RenalGuard
Sponsored by
The Royal Wolverhampton Hospitals NHS Trust
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Acute Renal Injury

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Patients undergoing surgery (elective or in-house urgent)
  2. Patient 18 years old and over
  3. Patient able to give written consent
  4. Patient at risk of developing AKI after cardiac surgery (at least one factor)

    1. Diabetics (IDDM or NIDDM) with normal kidney function pre-op
    2. Patients with eGFR 20-60
    3. Patients undergoing combined cardiac procedures when the CPB time is likely to exceed 120 minutes
    4. Patients with Hb of 12.5 g/dl or below
    5. Logistic Euroscore of 5 and above
  5. Patient not involved with another study

Exclusion Criteria:

  1. Emergency surgery
  2. Patient unable to give written consent
  3. Patient already dialysis dependent or eGFR <20
  4. Patient partaking in another study
  5. Pregnant patients

Sites / Locations

  • The Royal Wolverhampton NHS Trust

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

No Intervention

Arm Label

Study group

Control group

Arm Description

Patients will receive the RenalGuard system

Standard practice will be performed with no RenalGuard system

Outcomes

Primary Outcome Measures

Incidence of AKI as defined by the RIFLE criteria

Secondary Outcome Measures

Full Information

First Posted
November 23, 2016
Last Updated
September 1, 2021
Sponsor
The Royal Wolverhampton Hospitals NHS Trust
search

1. Study Identification

Unique Protocol Identification Number
NCT02974946
Brief Title
Kidney Protection Using the RenalGuard® System in Cardiac Surgery
Acronym
KIDNEY
Official Title
Kidney Protection Using the RenalGuard® System in Cardiac Surgery
Study Type
Interventional

2. Study Status

Record Verification Date
September 2021
Overall Recruitment Status
Completed
Study Start Date
January 2017 (Actual)
Primary Completion Date
June 12, 2019 (Actual)
Study Completion Date
September 22, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
The Royal Wolverhampton Hospitals NHS Trust

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This is a prospective randomised control trial 1:1 in patients at risk of developing Acute Kidney Injury after cardiac surgery comparing the RenalGuard® System to current medical treatment. 110 patients will be recruited for each group. The aim of the study is to assess whether the RenalGuard® system reduces Acute Kidney Injury (AKI) after cardiac surgery as compared to current practice.
Detailed Description
Patients undergoing elective or in-house urgent cardiac surgery will be approached for the KIDNEY study if they fulfil the inclusion criteria. Upon consent pre-operative blood tests will be as per the usual practice. Moreover, 2ml of the serum will be stored for NGAL analysis. Following the consenting process, patients will be randomised (envelop- based) into either having the RenalGuard® System (Study group) or current medical management (Control group). Study group: Patients in the study group will have the RenalGuard® System started in anaesthetic room once the peripheral line and arterial lines are sited. The RenalGuard® System will continue to run throughout the cardiac procedure in the operating room and up to 6 hours post-op after the patient has been transferred to the unit. Patients will be managed at a zero balance i.e. volume of the urine output will be matched to the volume of Hartmann's fluid infusion. Forced diuresis is then initiated. Control group: Patients in the control group will be managed as per current medical practice which will include no forced diuresis in operating room and the use of inotropes for maintenance of mean arterial pressure and intravenous furosemide for diuresis. An additional blood test (NGAL) at six hours post-op will be taken and would require 2mls of blood. The NGAL specimens will be dealt with by the biochemistry lab (centrifuged & stored) so that the specimens can be analysed in batches. Patients kidney function (U&Es) will be tested at the time of post-operatively as per usual practice (Day1, pre-discharge and as clinically indicated) and at the post-operative surgical out-patient visit. Pre-operative, intra-operative and post-operative data will be collected for each patient group.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Acute Renal Injury

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
None (Open Label)
Allocation
Randomized
Enrollment
220 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Study group
Arm Type
Experimental
Arm Description
Patients will receive the RenalGuard system
Arm Title
Control group
Arm Type
No Intervention
Arm Description
Standard practice will be performed with no RenalGuard system
Intervention Type
Device
Intervention Name(s)
RenalGuard
Primary Outcome Measure Information:
Title
Incidence of AKI as defined by the RIFLE criteria
Time Frame
50% rise in pre-op serum creatinine within 3 days of surgery

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Patients undergoing surgery (elective or in-house urgent) Patient 18 years old and over Patient able to give written consent Patient at risk of developing AKI after cardiac surgery (at least one factor) Diabetics (IDDM or NIDDM) with normal kidney function pre-op Patients with eGFR 20-60 Patients undergoing combined cardiac procedures when the CPB time is likely to exceed 120 minutes Patients with Hb of 12.5 g/dl or below Logistic Euroscore of 5 and above Patient not involved with another study Exclusion Criteria: Emergency surgery Patient unable to give written consent Patient already dialysis dependent or eGFR <20 Patient partaking in another study Pregnant patients
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Heyman Luckraz
Organizational Affiliation
Royal Wolverhampton NHS Trust
Official's Role
Principal Investigator
Facility Information:
Facility Name
The Royal Wolverhampton NHS Trust
City
Wolverhampton
State/Province
West Midlands
ZIP/Postal Code
WV10 0QP
Country
United Kingdom

12. IPD Sharing Statement

Citations:
PubMed Identifier
33236105
Citation
Luckraz H, Giri R, Wrigley B, Nagarajan K, Senanayake E, Sharman E, Beare L, Nevill A. Reduction in acute kidney injury post cardiac surgery using balanced forced diuresis: a randomized, controlled trial. Eur J Cardiothorac Surg. 2021 Apr 13;59(3):562-569. doi: 10.1093/ejcts/ezaa395.
Results Reference
result
PubMed Identifier
34429137
Citation
Luckraz H, Giri R, Wrigley B, Nagarajan K, Senanayake E, Sharman E, Beare L, Nevill A. Balanced forced-diuresis compared to control as a reno-protective approach in cardiac surgery: secondary outcome of a randomized controlled trial, assessment of neutrophil gelatinase-associated lipocalin levels. J Cardiothorac Surg. 2021 Aug 24;16(1):240. doi: 10.1186/s13019-021-01620-w.
Results Reference
result
PubMed Identifier
34414606
Citation
Luckraz H, Giri R, Wrigley B, Nagarajan K, Senanayake E, Sharman E, Beare L, Nevill A. Balanced forced-diuresis as a renal protective approach in cardiac surgery: Secondary outcomes of electrolyte changes. J Card Surg. 2021 Nov;36(11):4125-4131. doi: 10.1111/jocs.15925. Epub 2021 Aug 19.
Results Reference
result
PubMed Identifier
29071091
Citation
Luckraz H, Giri R, Wrigley B, Hennessy AM, Nicholas J, Nevill A. The use of the RenalGuard system in cardiac surgery with cardiopulmonary bypass: a first in man prospective, observational, feasibility pilot study. Open Heart. 2017 Oct 10;4(2):e000669. doi: 10.1136/openhrt-2017-000669. eCollection 2017.
Results Reference
derived

Learn more about this trial

Kidney Protection Using the RenalGuard® System in Cardiac Surgery

We'll reach out to this number within 24 hrs